Is It Too Late To Consider Liquidia After Its 182.6% 2025 Surge?

Simply Wall St.

Dec 16

If you are wondering whether Liquidia is still a smart buy after its huge run, you are not alone. This is exactly the kind of stock where valuation really matters. The share price has pulled back ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2591725256"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591725256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591725256?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2025-12-16 08:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591725256","market":"sg","top_or_hot":-1,"title":"Is It Too Late To Consider Liquidia After Its 182.6% 2025 Surge?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Liquidia is still a smart buy after its huge run, you are not alone. This is exactly the kind of stock where valuation really matters. The share price has pulled back ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/is-it-too-late-to-consider-liquidia-after-its-1826-2025-surg\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Liquidia After Its 182.6% 2025 Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Liquidia After Its 182.6% 2025 Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-16 08:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/is-it-too-late-to-consider-liquidia-after-its-1826-2025-surg><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Liquidia is still a smart buy after its huge run, you are not alone. This is exactly the kind of stock where valuation really matters. The share price has pulled back ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/is-it-too-late-to-consider-liquidia-after-its-1826-2025-surg\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/is-it-too-late-to-consider-liquidia-after-its-1826-2025-surg","article_id":"2591725256","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/is-it-too-late-to-consider-liquidia-after-its-1826-2025-surg","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591725256","pubTimestamp":1765845238,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Liquidia is still a smart buy after its huge run, you are not alone. This is exactly the kind of stock where valuation really matters.\nThe share price has pulled back about 2.3% over the last week, but it is still up 21.9% over 30 days and 182.6% year to date, with a 210.0% gain over the past year and 992.3% over five years.\nThose moves have been driven by growing optimism around Liquidia's pipeline and regulatory progress, with investors reacting positively to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LQDA":"Liquidia Technologies Inc"},"translate_title":"Liquidia 2025年飙升182.6%后，现在考虑是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"LQDA":0.9},"content_text":"If you are wondering whether Liquidia is still a smart buy after its huge run, you are not alone. This is exactly the kind of stock where valuation really matters. The share price has pulled back about 2.3% over the last week, but it is still up 21.9% over 30 days and 182.6% year to date, with a 210.0% gain over the past year and 992.3% over five years. Those moves have been driven by growing optimism around Liquidia's pipeline and regulatory progress, with investors reacting positively to developments that reduce perceived risk around its lead therapies. At the same time, shifts in sentiment across the biotech space have amplified every piece of company specific news, making the stock more volatile than the broader market. Despite all that excitement, Liquidia scores just 2 out of 6 on our valuation checks. Next, we will break down what different valuation methods say about the stock, and then finish with a more complete way to judge whether the current price really makes sense.  Liquidia scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. Approach 1: Liquidia Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a company is worth by projecting its future cash flows and discounting them back to today, so investors can compare that value to the current share price. For Liquidia, the 2 Stage Free Cash Flow to Equity model starts from last twelve months Free Cash Flow of roughly $116 million in the red, reflecting its investment heavy, pre profit profile. Analyst forecasts and Simply Wall St extrapolations then ramp Free Cash Flow up to about $942 million by 2035, with particularly rapid growth expected through the late 2020s as key therapies potentially gain traction. When all those projected cash flows are discounted back to today, the model produces an estimated intrinsic value of about $196.66 per share. Compared with the current share price, this implies the stock is roughly 82.6% undervalued. This suggests the market is still pricing in a lot more risk than the cash flow outlook alone would indicate. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Liquidia is undervalued by 82.6%. Track this in your watchlist or portfolio, or discover 908 more undervalued stocks based on cash flows. LQDA Discounted Cash Flow as at Dec 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Liquidia. Approach 2: Liquidia Price vs Sales For companies that are still unprofitable or reinvesting heavily, the price to sales ratio is often a straightforward way to gauge valuation because it focuses on how much investors are paying for each dollar of current revenue, rather than uncertain future earnings. In general, faster growth and lower perceived risk can justify a higher normal multiple, while slower growth or higher risk usually means a lower one is appropriate. Liquidia currently trades at about 43.0x sales, far above the broader Pharmaceuticals industry average of roughly 4.2x and well ahead of its peer group, which sits near 9.3x. On the surface, that kind of premium suggests a lot of future success is already priced in. To refine this view, Simply Wall St uses a proprietary Fair Ratio, which estimates what a justified price to sales multiple should be after factoring in earnings growth potential, industry dynamics, profit margins, company size and risk profile. For Liquidia, the Fair Ratio comes out at around 16.1x sales, a level that is tailored to the company, unlike simple peer or industry comparisons. With the current multiple of 43.0x sitting far above that Fair Ratio, the stock appears meaningfully overvalued on this metric. Result: OVERVALUED NasdaqCM:LQDA PS Ratio as at Dec 2025 PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1446 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Liquidia Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to connect your view of a company’s future with the numbers behind it. A Narrative is your story about Liquidia, captured as assumptions for fair value, future revenue growth, margins and risk, so you can see how the story translates into a concrete forecast and a single fair value estimate. On Simply Wall St, millions of investors build and explore Narratives on the Community page, using them as an easy tool to decide whether to buy or sell by comparing their Fair Value to the current share price. Because Narratives update automatically as new information, like news or earnings results, flows in, your story and valuation stay current without any number crunching. For Liquidia, one investor’s Narrative might price in rapid adoption of its lead therapy and strong margins, while another assumes slower uptake and continued cash burn, leading to very different fair values and, in turn, very different decisions about whether the stock is attractive at today’s price. Do you think there's more to the story for Liquidia? Head over to our Community to see what others are saying! NasdaqCM:LQDA 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}